Market News & Trends
Kymab & LifeArc Enter Strategic Partnership to Discover New Medicines Using Kymab’s IntelliSelect Technologies
The agreement will enable LifeArc to enhance its antibody drug discovery capabilities into new medicinal products with Kymab’s proprietary IntelliSelect technology platforms.
Global DNA Sequencing: Research, Applied & Clinical Markets
The global sequencing market should grow from $10.7 billion in 2018 to $24.4 billion by 2023, with a compound annual growth rate (CAGR) of 18.0% for the period of 2018-2023.
Athenex Announces US FDA Allowance of IND Application
Athenex, Inc. recently announced that the US FDA has allowed the company’s Investigational New Drug (IND) application for the clinical investigation of PT01 (Pegtomarginase) for…
Krystal Biotech Announces Positive Results from Phase 2 Clinical Trial, Receives RMAT Designation
Krystal Biotech, Inc. recently announced positive results from its Phase 2 placebo-controlled clinical trial of KB103 (GEM-2) study and an update on results from Phase1…
PREMIA & AmoyDx Announce Strategic Partnership to Establish Asia Cancer Clinical Genomic Network
Loxo Oncology, Inc. recently entered into a strategic partnership agreement with Amoy Diagnostics Co., Ltd. and PREMIA Holdings (HK) Ltd.
Cytel & Axio Join Forces to Create Industry Leader in Analytical Solutions for Drug Development
Cytel Inc. and Axio Research recently announced they have joined forces to create the largest global biometrics organization focused on delivering advanced analytical solutions for…
Samumed Doses First Subject in Phase 3 STRIDES-X-ray Trial
Samumed, LLC recently announced it has dosed the first patient in its Phase 3 STRIDES-X-ray trial of lorecivivint (SM04690), a CLK/DYRK inhibitor that modulates the…
CURE Pharmaceutical & Canopy Growth to Produce CBD Oral Thin Films
CURE Pharmaceutical recently announced it is collaborating with Canopy Growth Corporation to develop a new low-dose cannabidiol (CBD) oral thin film (OTF) using CURE’s patented…
Protalix BioTherapeutics Completes Enrollment in Phase 3 Trial
Protalix BioTherapeutics, Inc. recently announced the completion of enrollment in the Phase 3 BRIGHT clinical trial of pegunigalsidase alfa, or PRX‑102, for the treatment of…
Catalent to Purchase Bristol-Myers Squibb Facility
Bristol-Myers Squibb Company and Catalent, Inc. recently announced that Catalent has agreed to purchase Bristol-Myers Squibb’s oral solid, biologics, and sterile product manufacturing and packaging…
Bavarian Nordic Initiates Phase 3 Trial of Vaccine
Bavarian Nordic A/S recently announced the initiation of a pivotal Phase 3 trial of the freeze-dried formulation of MVA-BN smallpox vaccine in 1,110 healthy, vaccinia-naïve…
Aclaris Therapeutics Announces Positive 6-Month Results from Phase 2 Clinical Trial
Aclaris Therapeutics, Inc. recently announced positive results from a Phase 2 open-label clinical trial of ATI-502 (AGA-201), an investigational topical Janus Kinase (JAK) 1/3 inhibitor, in patients with androgenetic alopecia (AGA), a condition commonly known as male/female-pattern baldness.
iBio Announces First Agreement for Fill-Finish Services
iBio, Inc. recently announced the activation of its new cGMP sterile fill-finish services operation via the signing of a supply agreement with a clinical-stage biopharmaceutical company developing breakthrough gene and cell therapies.
Gilead & Nurix Establish Lucrative Strategic Collaboration
Gilead Sciences, Inc. and Nurix Therapeutics, Inc. recently announced a global strategic collaboration to discover, develop, and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases.
Sanofi & Google to Develop New Healthcare Innovation Lab
Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping into the power of emerging data technologies.
Genesis Drug Discovery & Development Expands Preclinical Contract Research Portfolio With Acquisition
Genesis Drug Discovery & Development (GD3), the contract research organization (CRO) of Genesis Biotechnology Group (GBG), recently announced that it has expanded its drug development services through…
Owlstone Medical Announces a Novel Approach to Breath-Based Testing
Owlstone Medical, the global leader in Breath Biopsy for applications in early disease detection and precision medicine, recently announced the development of an innovative alternative…
Akari Therapeutics’ Nomacopan Demonstrates Positive Early Safety & Efficacy
Akari Therapeutics, Plc, a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated,…
Developing Microfluidic Routes to Effective Nanoparticle Drug Delivery Systems
A Dolomite Microfluidics’ set-up is helping researchers in the University of Manchester’s Division of Pharmacy and Optometry to enhance drug delivery. Dr Annalisa Tirella explained:…
Array BioPharma Acquisition Will Accelerate Pfizer’s Position as a Major Player in Colorectal Cancer
Following the news that Pfizer has agreed to acquire Array BioPharma in a deal worth approximately $11.4 billion, Tajekesa Chapman, PhD, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers her view on the potential of this buy-out on the treatment of colorectal cancers.
